Mubadala Investment Company in Recursion Pharmaceuticals, Inc.
Completed. First disclosed April 15, 2021, in a Form 3 (source).
- Investor
- Mubadala Investment Company (United Arab Emirates)
- Target
- Recursion Pharmaceuticals, Inc. (EDGAR CIK 1601830)
- Target country
- United States
- Sector
- Health and Life Sciences (SIC 2836)
- First disclosed
- April 15, 2021, Form 3
- Amount
- Not stated
- Stake at first disclosure
- 5.7%
- Latest stated stake
- 0.0% (as filed) (December 23, 2025)
Source Filings and Releases
| Date | Document | Stated stake | Link |
|---|---|---|---|
| April 15, 2021 | Form 3 | Not applicable | View |
| April 20, 2021 | Form 4 | Not applicable | View |
| April 26, 2021 | Schedule 13D | 5.7% | View |
| November 4, 2021 | Schedule 13D/A | 5.5% | View |
| October 31, 2022 | Schedule 13D/A | 6.3% | View |
| October 31, 2022 | Form 4 | Not applicable | View |
| January 13, 2023 | Form 4 | Not applicable | View |
| January 26, 2023 | Form 4 | Not applicable | View |
| January 27, 2023 | Form 4 | Not applicable | View |
| February 2, 2023 | Form 4 | Not applicable | View |
| February 13, 2023 | Form 4 | Not applicable | View |
| February 14, 2023 | Form 4 | Not applicable | View |
| February 15, 2023 | Form 4 | Not applicable | View |
| February 17, 2023 | Form 4 | Not applicable | View |
| February 21, 2023 | Form 4 | Not applicable | View |
| February 22, 2023 | Form 4 | Not applicable | View |
| February 23, 2023 | Form 4 | Not applicable | View |
| February 24, 2023 | Form 4 | Not applicable | View |
| February 27, 2023 | Form 4 | Not applicable | View |
| February 28, 2023 | Form 4 | Not applicable | View |
| March 1, 2023 | Form 4 | Not applicable | View |
| March 2, 2023 | Form 4 | Not applicable | View |
| March 3, 2023 | Form 4 | Not applicable | View |
| December 23, 2025 | Schedule 13D/A | 0.0% (as filed) | View |
Cite: Middle East Forum, “Mubadala Investment Company in Recursion Pharmaceuticals, Inc.,” Gulf Sovereign Holdings, accessed October 13, 2026, https://statemoney.meforum.org/deal/mubadala-recursion-pharmaceuticals-inc-1601830/.
Gulf money also reaches U.S. universities and lobbyists: the Influence Tracker holds Section 117 gift and contract disclosures and FARA registrations, and the Campus Watch Map places that funding on specific campuses.